Retrieve available abstracts of 16 articles: HTML format
Single Articles
August 2025
BHATNAGAR S, Revuri V, Merali C, Wang B, et al A Novel Imidazoquinoline With TLR 7/8, STING, and Inflammasome Activity
Demonstrates Antitumor Efficacy in Mouse Melanoma and Neu-Driven Mammary
Adenocarcinoma.
J Immunother. 2025 Aug 6. doi: 10.1097/CJI.0000000000000571. PubMedAbstract available
July 2025
STEIMLE AK, Cho SY, Menon N, Jeraj R, et al ctDNA Dynamics Identifies Pseudoprogression in a Metastatic Melanoma Patient
Treated With Nivolumab/Relatlimab.
J Immunother. 2025 Jul 7. doi: 10.1097/CJI.0000000000000569. PubMedAbstract available
May 2025
TANG J, Zhu S, Zhu L Integrated Single-Cell and Bulk RNA Sequencing Analysis Identifies a Regulated
Cell Death-Related Gene Signature for Predicting Prognosis and Therapeutic
Responses in Cutaneous Melanoma.
J Immunother. 2025 May 30. doi: 10.1097/CJI.0000000000000564. PubMedAbstract available
April 2025
SHAO YF, Baca Y, Hinton A, Xiu J, et al Immune Profiling of Uveal Melanoma Liver Metastases and Response to Checkpoint
Inhibitors.
J Immunother. 2025 Apr 15. doi: 10.1097/CJI.0000000000000558. PubMedAbstract available
November 2024
FAN C, Li Y, Jiang A, Zhao R, et al Machine Learning-enhanced Signature of Metastasis-related T Cell Marker Genes for
Predicting Overall Survival in Malignant Melanoma.
J Immunother. 2024 Nov 7. doi: 10.1097/CJI.0000000000000544. PubMedAbstract available
October 2024
FESSLER K, Zhang J, Sandhu AK, Hui Y, et al Brief Communication: Combination of an MIP3alpha-Antigen Fusion Therapeutic DNA
Vaccine With Treatments of IFNalpha and 5-Aza-2'Deoxycytidine Enhances Activated
Effector CD8+ T Cells Expressing CD11c in the B16F10 Melanoma Model.
J Immunother. 2024 Oct 14. doi: 10.1097/CJI.0000000000000542. PubMedAbstract available
August 2024
PERSA OD, Hassel JC, Steeb T, Erdmann M, et al Brief Communication: Treatment Outcomes for Advanced Melanoma of Unknown Primary
Compared With Melanoma With Known Primary.
J Immunother. 2024 Aug 29. doi: 10.1097/CJI.0000000000000537. PubMedAbstract available
July 2024
WANG ZZ, Yao GT, Wang LZ, Zhu YJ, et al Increased Expression and Prognostic Significance of BYSL in Melanoma.
J Immunother. 2024 Jul 9. doi: 10.1097/CJI.0000000000000530. PubMedAbstract available
February 2024
BASIR S, Bosiers J, Westgeest HM, Yick DCY, et al Bronchiolitis after Combination Immunotherapy With Ipilimumab and Nivolumab in a
Melanoma Patient.
J Immunother. 2024 Feb 27. doi: 10.1097/CJI.0000000000000509. PubMedAbstract available
ARAK H, Erkilic S, Yaslikaya S, Eylemer Mocan E, et al The Effectiveness of Adjuvant PD-1 Inhibitors in Patients With Surgically
Resected Stage III/IV Acral Melanoma.
J Immunother. 2024 Feb 7. doi: 10.1097/CJI.0000000000000508. PubMedAbstract available
DE JOODE K, Mora AR, van Schaik RHN, Zippelius A, et al Effects of CTLA-4 Single Nucleotide Polymorphisms on Toxicity of
Ipilimumab-Containing Regimens in Patients With Advanced Stage Melanoma.
J Immunother. 2024 Feb 6. doi: 10.1097/CJI.0000000000000506. PubMedAbstract available
September 2023
D'ANNIBALLE VM, Huang MN, Lueck BD, Nicholson LT, et al Antigen-loaded Monocyte Administration and Flt3 Ligand Augment the Antitumor
Efficacy of Immune Checkpoint Blockade in a Murine Melanoma Model.
J Immunother. 2023 Sep 20. doi: 10.1097/CJI.0000000000000487. PubMedAbstract available
SCHON V, Stocker D, Jungst C, Dummer R, et al Immune-Related Sclerosing Cholangitis and Subsequent Pyogenic Liver Abscesses in
Two Patients With Melanoma Treated by Triplet Therapy: A Case Report.
J Immunother. 2023 Sep 19. doi: 10.1097/CJI.0000000000000486. PubMedAbstract available
June 2023
BUCHBINDER EI, Pfaff KL, Turner MM, Manos M, et al Brief Communication on Pathologic Assessment of Persistent Stable Metastatic
Lesions in Patients Treated With Anti-CTLA-4 or Anti-CTLA-4 + Anti-PD-1 Therapy.
J Immunother. 2023;46:192-196. PubMedAbstract available
May 2023
ZHANG L, Cao L, Li S, Wang L, et al Biologically Interpretable Deep Learning To Predict Response to Immunotherapy In
Advanced Melanoma Using Mutations and Copy Number Variations.
J Immunother. 2023 May 24. doi: 10.1097/CJI.0000000000000475. PubMedAbstract available
April 2023
VAN ZEIJL MCT, van Breeschoten J, de Wreede LC, Wouters MWJM, et al Real-world Outcomes of Ipilimumab Plus Nivolumab Combination Therapy in a
Nation-wide Cohort of Advanced Melanoma Patients in the Netherlands.
J Immunother. 2023 Apr 28. doi: 10.1097/CJI.0000000000000468. PubMedAbstract available